Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Angiotensin converting enzyme inhibition does not affect response to exogenous angiotensin II in the forearm of mild-moderate hypertensive patients

  • 18 Accesses

  • 1 Citations

Abstract

It has been proposed that the supression of endogenous levels of angiotensin II by angiotensin converting enzyme inhibition, may result in up-regulation of vascular AT1 receptors.

This study evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the human forearm of patients with mild-moderate hypertension. Patients received in random order, enalapril (20 mg) or matched placebo daily for 2 weeks. Forearm blood flow response to increasing doses of angiotensin II was measured using venous occlusion plethysmography at the begining of the study and at the end of each 2 week treatment period.

Treatment with enalapril significantly reduced plasma angiotensin II levels and supine blood pressure compared to placebo. The percentage reductions in forearm blood flow in the infused arm, in response to the maximum dose of angiotensin II (50 pmol·min−1) were 53.2% at baseline, 51.4% on placebo and 59.5% on enalapril. The differences were not significantly different.

This study demonstrates that supression of plasma angiotensin II does not enhance the response to exogenous intra-arterial angiotensin II in the human forearm of mild-moderately hypertensive patients.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Gunther S, Gimbrone MA Jr, Alexander RW (1980) Regulation by angiotensin II of its receptors in resistance blood vessels. Nature 287(5779): 230–232

  2. 2.

    Reid WD, Laragh JH (1965) Sodium and potassium intake, blood pressure and pressor response to angiotensin. Proc Soc Exp Biol Med 120: 26–29

  3. 3.

    Healy JK, Suszkiw JB, Dennis VW, Schreiner GE (1969) Effect of aldosterone and salt intake on renal and pressor actions of angiotensin. Nephron 3: 329–343

  4. 4.

    Kitami Y, Okura T, Marumoto K, Wakamiya R, Hiwada K (1992) Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Comm 188: 446–452

  5. 5.

    Kaplan NM, Silah JG (1964) The effect of angiotensin II on the blood pressure in humans with hypertensive disease. J Clin Invest 43: 659–669

  6. 6.

    Skorecki KL, Ballermann BJ, Rennke HG, Brenner BM (1983) Angiotensin II receptor regulation in isolated renal glomeruli. Fed Proc 42: 3064–3070

  7. 7.

    Bouscarel B, Wilson PB, Blackmore PF, Lynch CJ, Exton JH (1988) Agonist-induced down-regulation of the angiotensin II receptor in primary cultures of rat hepatocytes. J Biol Chem 263: 14920–14924

  8. 8.

    Iwai N, Inagami T (1992) Regulation of the expression of the rat angiotensin II receptor mRNA. Biochem Biophys Res Comm 182: 1094–1099

  9. 9.

    Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y, Inagami T (1991) Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem Biophys Res Comm 177: 299–304

  10. 10.

    Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia J (1989) Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 163: 284–291

  11. 11.

    Sasamura H, Hein L, Krieger J, Pratt R, Kobilka B, Dzau V (1992) Cloning characterization and expression of two angiotensin receptor (AT1) isoforms from the mouse genome. Biochem Biophys Res Commun 185: 253–259

  12. 12.

    Whitney RJ (1953) The measurement of volume changes in human limbs. J Physiol 121: 1–27

  13. 13.

    Düsterdieck G, McElwee G (1971) Estimation of angiotensin II concentration in huuman plasma: some applications to physiological and clinical states. Eur J Clin Invest 2:32–35

  14. 14.

    Morton JJ, Webb D (1985) Measurement of plasma angiotensin II. Clin Sci 68: 483–484

  15. 15.

    Jamieson MJ, Webster J, Witte K, Huggins M, MacDonald TM, de Beaux A, Petrie JC (1990) An evaluation of the A&D UA-751 sphygmomanometer. J Hypertension 8: 607–619

  16. 16.

    Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ (1989) Local inhibition of converting enzyme and vascular responses to angiotensin II and bradykinin in the human forearm. J Physiol 412: 543–555

  17. 17.

    Rodda BE, Tsianco MC, Bolognes JA, Kersten MK (1988) Clinical development. In Peace KE (ed) Biopharmaceutical Statistics for Drug Development. Dekker, New York, pp 273–328

  18. 18.

    Greenfield ADM, Patterson GC (1954) Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol 125: tprint

  19. 19.

    Reagan LP, Ye X, Maretzski CH, Fluharty SJ (1993) Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells. J Neurochem 60:24–31

  20. 20.

    Kahn CR, Neville DM Jr, Roth J (1973) Insulin-receptor interaction in the obese hyperglycaemic mouse. A model of insulin resistance. J Biol Chem 248:244–250

  21. 21.

    Lesniak MA, Roth J (1976) Regulation of receptor concentration by homologous hormone. Effect of human growth hormone on its receptor in IM-9 lymphocytes. J Biol Chem 251:3720–3729

Download references

Author information

Correspondence to D. Lyons.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lyons, D., Webster, J. & Benjamin, N. Angiotensin converting enzyme inhibition does not affect response to exogenous angiotensin II in the forearm of mild-moderate hypertensive patients. Eur J Clin Pharmacol 47, 147–150 (1994). https://doi.org/10.1007/BF00194964

Download citation

Key words

  • Angiotensin II
  • Enalapril
  • Hypertension
  • receptor
  • forearm blood flow